FDA Endorses NfL Biomarker for Accelerated ALS Approval; Clene to File NDA in Q3 2026

What happened

Clene announced that FDA meeting minutes confirm NfL biomarker data may support an accelerated approval NDA for CNM-Au8 in ALS, reversing previous regulatory skepticism. The company expects to submit the NDA in Q3 2026, positioning CNM-Au8 as a potential first-in-class therapy for a high-unmet-need indication. However, Clene's cash position remains precarious at ~$7.3M with a going-concern disclosure, making financing critical to fund the NDA and confirmatory Phase 3 trial. The withdrawal of Relyvrio underscores the commercial opportunity but also the high bar for confirmatory endpoints. While this news is a significant positive catalyst, execution risk persists around funding and eventual trial results.

Implication

The FDA's acceptance of NfL as a surrogate endpoint removes a key regulatory overhang and boosts the probability of accelerated approval for CNM-Au8. However, Clene must secure funding to submit the NDA and run confirmatory trials; failure to do so could lead to severe dilution or insolvency. If financing is obtained, the stock could re-rate significantly given the large ALS market and lack of approved oral therapies. Investors should watch for partnership or equity offering announcements in the coming months. The confirmatory Phase 3 still poses substantial risk, and any safety or efficacy issues could derail the asset.

Thesis delta

Previous WAIT/NEUTRAL stance was driven by FDA skepticism on biomarkers and acute financing risk. This news materially de-risks the regulatory pathway, upgrading the thesis to Speculative Buy contingent on financing clarity. The primary risk shifts from regulatory uncertainty to financial execution.